Table 1

Clinical features of the patients with RA from whom nodules were obtained

Patient NoNodule codeSexAgeDisease duration (years)DMARDInfliximabRFSJCCRP (mg/l)ACR response atAge of the nodule (years)Other extra-articular manifestations
6 Weeks (%)3 Months (%)
DMARD, disease modifying antirheumatic drug; MTX, methotrexate (given at a dose of 10–20 mg/week in all patients); RF, rheumatoid factor; SJC, swollen joint count; CRP, C reactive protein serum levels; NA, not available.
11F5923Gold saltsNo+35.13None
22F465MTXNo+22.42None
33M714MTXNo+31.21None
44F6320MTXBaseline+1084Sicca syndrome
55M655MTXBaseline+21342Pulmonary fibrosis
66F6620MTXBaseline+6135None
47F6320MTX2 Months+11NA<20>204Sicca syndrome
58M655MTX4 Months+924>20>202Pulmonary fibrosis
69F6721MTX12 Months+711>20>205Nailfold vasculitis
710F652MTX12 Months+622>20>500.25None
811M559MTX30 Months650>20>207None